Kratom Alkaloids: A Blood-Brain Barrier Specific Membrane Permeability Assay-Guided Isolation and Cyclodextrin...

Area of Science:

• Pharmacology and Natural Products Chemistry
• Drug Delivery and Bioavailability Enhancement

Background:

• Mitragynine, an atypical opioid analgesic, offers a unique mechanism and favorable side-effect profile.
• Kratom alkaloids possess potential therapeutic value, but their central nervous system (CNS) penetration and bioavailability require optimization.

Purpose of the Study:

• To optimize alkaloid extraction from kratom leaves for enhanced CNS penetration.
• To identify and isolate kratom alkaloids with significant blood-brain barrier (BBB) permeability.
• To investigate cyclodextrin (CD) complexation for improving the bioavailability of these alkaloids.

Main Methods:

• Optimized extraction and purification sequence involving CPC, flash chromatography, and preparative HPLC.
• In vitro blood-brain barrier permeability assessment using the PAMPA-BBB model.
• Affinity capillary electrophoresis and phase-solubility studies to evaluate alkaloid-cyclodextrin complexation with nearly 40 CD derivatives.

Main Results:

• Mitragynine, speciociliatine, speciogynine, and paynantheine demonstrated excellent in vitro BBB permeability.
• The optimized isolation procedure successfully yielded these four BBB-penetrant alkaloids.
• Neutral and negatively charged cyclodextrins formed complexes with all four alkaloids, with negatively charged derivatives (Sugammadex, Subetadex, sufoalkylated-beta-CDs) showing the highest stability constants (>1000 M⁻¹).

Conclusions:

• The study successfully optimized kratom alkaloid extraction and identified key compounds with high BBB permeability.
• Cyclodextrin complexation, particularly with specific negatively charged derivatives, is a promising strategy for enhancing the bioavailability of these kratom alkaloids.
• These findings provide a foundation for further development of kratom-derived compounds for therapeutic applications.